RPG Investment Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

RPG Investment Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-17,160	Closed	-$1.53M	–	405
2017 Q4	$1.53M	Sell	17,160 -300	-2%	-$26.1K	0.37%	71
2017 Q3	$1.63M	Sell	17,460 -20	-0.1%	-$1.77K	0.41%	71
2017 Q2	$1.59M	Buy	17,480 +380	+2%	+$34.6K	0.43%	68
2017 Q1	$1.5M	Sell	17,100 -100	-0.6%	-$8.9K	0.44%	69
2016 Q4	$1.42M	Sell	17,200 -700	-4%	-$60.2K	0.48%	63
2016 Q3	$1.66M	Sell	17,900 -800	-4%	-$75.3K	0.52%	65
2016 Q2	$1.45M	Sell	18,700 -100	-0.5%	-$8.5K	0.39%	75
2016 Q1	$1.55M	Sell	18,800 -400	-2%	-$32.5K	0.6%	58
2015 Q4	$2.01M	Buy	+19,200	New	+$2M	0.75%	50

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RPG Investment Advisory's BMRN Position: Q1 2018 in Review

RPG Investment Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 17,160 shares — an estimated $1.53M sold.

RPG Investment Advisory first reported a position in BMRN in Q4 2015 and held it in 9 quarters. The position peaked at $2.01M in Q4 2015. 430 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

RPG Investment Advisory reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
RPG Investment Advisory sold 17,160 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $1.53M.
RPG Investment Advisory first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 9 quarters.
RPG Investment Advisory's BioMarin Pharmaceuticals position peaked at $2.01M in Q4 2015.
430 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on RPG Investment Advisory's 13F filing for Q1 2018, filed 15 May 2018.